Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections

被引：73

作者：

Dropulic, L. K. ^{[1
]}

Cohen, J. I. ^{[1
]}

机构：

[1] NIH, Med Virol Sect, Lab Clin Infect Dis, Bethesda, MD 20892 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 88卷 / 05期

关键词：

HEPATITIS-B-VIRUS; HELICASE-PRIMASE INHIBITOR; BENZIMIDAZOLE D-RIBONUCLEOSIDES; ANTIPOXVIRUS COMPOUND ST-246; LIPID-ESTER PRODRUGS; ALKOXYALKYL ESTERS; ANIMAL-MODELS; CYCLIC CIDOFOVIR; DOUBLE-BLIND; BAY; 57-1293;

D O I：

10.1038/clpt.2010.178

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

All the currently available antiviral agents used in the treatment of double-stranded (ds) DNA viruses, with the exception of interferon-alpha, inhibit the same target, the viral DNA polymerase. With increasing reports of the development of resistance of herpes simplex virus (HSV), cytomegalovirus (CMV), and hepatitis B virus (HBV) to some of these drugs, new antiviral agents are needed to treat these infections. Additionally, no drugs have been approved to treat several DNA virus infections, including those caused by adenovirus, smallpox, molluscum contagiosum, and BK virus. We report the status of 10 new antiviral drugs for the treatment of dsDNA viruses. CMX-001 has broad activity against dsDNA viruses; 3 helicase-primase inhibitors, maribavir, and FV-100 have activity against certain herpesviruses; ST-246 inhibits poxviruses; GS-9191 inhibits papillomaviruses; and clevudine and emtricitabine are active against HBV. Most of these drugs have completed at least phase I trials in humans, and many are in additional clinical trials.

引用

页码：610 / 619

页数：10

共 55 条

[1] Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox [J].

Adams, Mathew M. ;

Rice, Amanda D. ;

Moyer, R. W. .

JOURNAL OF VIROLOGY, 2007, 81 (20) :11084-11095

[2]

Baumeister Judith, 2007, Antiviral Chemistry & Chemotherapy, V18, P35

[3] Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro [J].

Beadle, JR ;

Hartline, C ;

Aldern, KA ;

Rodriguez, N ;

Harden, E ;

Kern, ER ;

Hostetler, KY .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2381-2386

[4] ST-246 Inhibits In Vivo Poxvirus Dissemination, Virus Shedding, and Systemic Disease Manifestation [J].

Berhanu, Aklile ;

King, David S. ;

Mosier, Stacie ;

Jordan, Robert ;

Jones, Kevin F. ;

Hruby, Dennis E. ;

Grosenbach, Douglas W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (12) :4999-5009

[5] Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293 [J].

Betz, UAK ;

Fischer, R ;

Kleymann, G ;

Hendrix, M ;

Rübsamen-Waigmann, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1766-1772

[6] Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection [J].

Bidanset, DJ ;

Beadle, JR ;

Wan, WB ;

Hostetler, KY ;

Kern, ER .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (03) :499-503

[7] Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action [J].

Biron, KK ;

Harvey, RJ ;

Chamberlain, SC ;

Good, SS ;

Smith, AA ;

Davis, MG ;

Talarico, CL ;

Miller, WH ;

Ferris, R ;

Dornsife, RE ;

Stanat, SC ;

Drach, JC ;

Townsend, LB ;

Koszalka, GW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2365-2372

[8]

Biswas Subhajit, 2007, Antiviral Chemistry & Chemotherapy, V18, P13

[9] Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model [J].

Buller, RM ;

Owens, G ;

Schriewer, J ;

Melman, L ;

Beadle, JR ;

Hostetler, KY .

VIROLOGY, 2004, 318 (02) :474-481

[10]

Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P532

← 1 2 3 4 5 6 →